This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Role of Proteomics in Diagnosing Sarcoidosis

This study has been completed.
Information provided by (Responsible Party):
marjolein drent, Maastricht University Medical Center Identifier:
First received: February 14, 2008
Last updated: November 5, 2012
Last verified: November 2012
Sarcoidosis is a multi-systemic disorder, meaning that it can involve any organ in the body and that its clinical presentation is highly variable. In 90% of all sarcoidosis cases the lungs are affected. It is difficult to give a concise definition of sarcoidosis due to the fact that its exact cause is still unknown. Consequently, diagnosing the disease is also rather difficult. Up till now, sarcoidosis is generally diagnosed by using general clinical methods to evaluate the status of the lung including a chest X-ray, lung biopsy and bronchoalveolar lavage (BAL). However, some of these methods are considered to be rather invasive and, even more important, non-conclusive. Therefore, the current study has been designed to evaluate the use of a new technique, called SELDI-TOF mass spectrophotometry, for the diagnosis of sarcoidosis. This technique enables the analysis of all enzymes present in the blood of sarcoidosis patients which may hopefully lead to creating a disease-specific protein-profile that may facilitate the recognition of sarcoidosis. Moreover, these results will be compared with other currently used laboratory parameters.


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Proteomics as a Tool for Biomarker Detection in Sarcoidosis

Resource links provided by NLM:

Further study details as provided by marjolein drent, Maastricht University Medical Center:

Primary Outcome Measures:
  • protein profile in blood [ Time Frame: within 1 month after obtaining sample ]

Secondary Outcome Measures:
  • CYP and TNF polymorphisms [ Time Frame: within 6 months after obtaining sample ]

Biospecimen Retention:   Samples With DNA
Blood will be collected from all participants, but all samples will be stored anonymously.

Enrollment: 1000
Study Start Date: March 2005
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
sarcoidosis patients
healthy volunteers and other interstitial lung disease (ILD) patients


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients visiting the out-patient clinic of the university hospital Maastricht.

Inclusion Criteria:

  • Clinical diagnosis of pulmonary sarcoidosis stage I-IV

Exclusion Criteria:

  • Non-smoking
  • No treatment for extra-pulmonary symptoms of sarcoidosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00626938

Maastricht University Medical Centre
Maastricht, Netherlands, 6202 AZ
Sponsors and Collaborators
Maastricht University Medical Center
Study Director: Marjolein Drent, Prof,MD,PhD University Hospital Maastricht, Departement of Respiratory Medicine
Principal Investigator: Otto Bekers, PhD University Hospital Maastricht, Departement of Clinical Chemistry
Principal Investigator: Christine Voorter, PhD University Hospital Maastricht, Departement of Tissue Typing
Study Chair: Marja P van Dieijen-Visser, Prof,MSc,PhD University Hospital Maastricht, Departement of Clinical Chemistry
  More Information

Additional Information:
Responsible Party: marjolein drent, Prof. Marjolein Drent, Maastricht University Medical Center Identifier: NCT00626938     History of Changes
Other Study ID Numbers: MEC 04-145.11
Study First Received: February 14, 2008
Last Updated: November 5, 2012

Keywords provided by marjolein drent, Maastricht University Medical Center:
protein profile
TNF-alpha polymorphisms

Additional relevant MeSH terms:
Lymphoproliferative Disorders
Lymphatic Diseases processed this record on August 18, 2017